Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Global Industry Bodies Urge Wider Use Of COVID-19-Related Regulatory Flexibilities

Harmonized Inspection Practices Are One Way Forward

Executive Summary

A range of steps have been taken to allow the scale-up of manufacturing of COVID-19 products during the pandemic. Now industry says the use of these flexibilities needs to be expanded to enhance the current pandemic response and rapidly increase product supply.

You may also be interested in...



EU Joint Regulatory Assessment Project Bears Fruit In COVID-19

The European Medicines Agency has reported progress with a collaborative project that involves other regulators in its assessments of COVID-19 products, and with the EU Medicines for All initiative for evaluating products for non-EU markets.

Pandemic Treaty Could Have IP & Other Implications For Pharma

Equitable access to pandemic medicines and vaccines will be at the core of the WHO’s future global pandemic treaty. Exactly what this will mean for the pharmaceutical industry remains to be seen, but it is likely that companies wanting access to virus samples and other materials will need to agree to benefit sharing in the form of IP and technology transfer.

‘We Need Help,’ Says EMA Chief Amid COVID-19 & Burgeoning Workload

COVID-19, resource constraints and a forthcoming expansion of its responsibilities are piling the pressure on the EU regulator.

Topics

UsernamePublicRestriction

Register

PS145157

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel